Pharmaceuticals, Biotechnology and Life Sciences
MGC Pharmaceuticals, a European based specialising in the production and development of plant derived medicines, announced positive pre-clinical trial results from the recently completed Pre-clinical Chronic Toxicology Evaluation of 14 days oral dose of CimetrA.
MGC Pharmaceuticals Ltd, a European based bio-pharma company specialising in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare , a part of UK health care group, Sciensus, for the distribution of CannEpil and CogniCann in key European territories and the UK
CannEpil+ , based on CannEpil, designed by MGC Pharma to treat Refractory Epilepsy, has been approved for import into the UK by the Medicines and Healthcare products Regulatory Agency via its UK distribution and clinical access partner Elite Pharmaco.
MGC Pharmaceuticals, a specialist in phytocannabinoid-derived medicines, has signed a binding US Market Supply and Distribution Agreement with US-based AMC Holdings, with minimum orders of $24 million for MGC products including CannEpil®, CogniCann® and CimetrA™ over the initial 3 year period.